| Schedule of intangible assets |
| | | | | | | | | September 30, | | December 31, | | | 2023 | | 2022 | Acquired technology – Polytherapeutics | | $ | 40,433 | | $ | 40,433 | Technology license – Skinvisible | | | 1,000,000 | | | 1,000,000 | Total cost | | | 1,040,433 | | | 1,040,433 | Accumulated amortization | | | (413,904) | | | (335,872) | Net book value | | $ | 626,529 | | $ | 704,561 |
|
| | | | | | | | | December 31, | | December 31, | | | 2022 | | 2021 | Acquired technology – Polytherapeutics | | $ | 40,433 | | $ | 40,433 | Technology license – Skinvisible | | | 1,000,000 | | | 1,000,000 | Total cost | | | 1,040,433 | | | 1,040,433 | Accumulated amortization | | | (335,872) | | | (231,829) | Net book value | | $ | 704,561 | | $ | 808,604 |
|